The State of Systematic Therapies in Clinic for Hepatobiliary Cancers
Weixun Chen,Zhengnan Hu,Ganxun Li,Lei Zhang,Tao Li
DOI: https://doi.org/10.2147/jhc.s454666
2024-03-27
Journal of Hepatocellular Carcinoma
Abstract:Weixun Chen, 1 Zhengnan Hu, 1 Ganxun Li, 1 Lei Zhang, 1 Tao Li 2 1 Hepatic Surgery Centre, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, People's Republic of China; 2 Department of Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430022, People's Republic of China Correspondence: Tao Li; Lei Zhang, Email ; Hepatobiliary cancer (HBC) includes hepatocellular carcinoma and biliary tract carcinoma (cholangiocarcinoma and gallbladder carcinoma), and its morbidity and mortality are significantly correlated with disease stage. Surgery is the cornerstone of curative therapy for early stage of HBC. However, a large proportion of patients with HBC are diagnosed with advanced stage and can only receive systemic treatment. According to the results of clinical trials, the first-line and second-line treatment programs are constantly updated with the improvement of therapeutic effectiveness. In order to improve the therapeutic effect, reduce the occurrence of drug resistance, and reduce the adverse reactions of patients, the treatment of HBC has gradually developed from single-agent therapy to combination. The traditional therapeutic philosophy proposed that patients with advanced HBC are only amenable to systematic therapies. With some encouraging clinical trial results, the treatment concept has been revolutionized, and patients with advanced HBC who receive novel systemic combination therapies with multi-modality treatment (including surgery, transplant, TACE, HAIC, RT) have significantly improved survival time. This review summarizes the treatment options and the latest clinical advances of HBC in each stage and discusses future direction, in order to inform the development of more effective treatments for HBC. Keywords: hepatobiliary cancer, systemic treatment, combination therapies Primary hepatobiliary cancer includes hepatocellular carcinoma (HCC) and biliary tract carcinoma (BTC), the latter of which is stratified into cholangiocarcinoma (CCA) (ie, intrahepatic CCA (iCCA), perihilar CCA and distal CCA (eCCA)) and gallbladder carcinoma (GBC). Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed and the third most lethal malignancy. 1 Hepatitis B virus (HBV) infection is the major aetiological factor in HCC worldwide, accounting for ~50% of cases. 2 The risk of HCC due to hepatitis C virus (HCV) infection has been significantly reduced as patients have achieved a sustained virological response (SVR) with antiviral drugs. Nevertheless, patients with HCV-induced cirrhosis are considered to be at high risk for HCC even after HCV clearance. 3 In addition, chronic alcohol consumption, non-alcoholic steatohepatitis (NASH) and environmental (aflatoxin, aristolochic acid and tobacco) factors have been identified as contributing to cancer development through different specific pathways. 4,5 Other less common risk factors for HCC include cirrhosis caused by primary biliary cholangitis (PBC), hemochromatosis, and α1-antitrypsin deficiency. PBC is an autoimmune disease that destroys the small bile ducts in the liver, which can ultimately lead to cirrhosis and indirectly cause liver cancer. 6 Hemochromatosis is a genetic disease that leads to an excess of iron in the body. The surplus iron is stored in organs, including the liver, which can cause a series of problems, including hepatitis, cirrhosis, and liver cancer. Alpha-1 antitrypsin deficiency is a genetic disease characterized by a lack of a protein called alpha-1 antitrypsin, which can potentially harm the lungs and liver. Studies have shown that alpha-1 antitrypsin deficiency is associated with cirrhosis and liver cancer. These factors, although less common than viral hepatitis, alcoholic liver disease, or non-alcoholic fatty liver disease (NAFLD), are still noteworthy risk factors for HCC. 7 The age-standardized death rate for intrahepatic cholangiocarcinoma (iCCA) increased from 2.15 per 100,000 people in 2009 to 2.95 per 100,000 people in 2018. Similarly, the age-standardized death rate for extrahepatic cholangiocarcinoma (eCCA) increased from 0.28 per 100,000 people in 2009 to 0.39 per 100,000 people in 2018. In contrast, over the course of 10 years, the death rate related to gallbladder cancer decreased from 1.0 per 100,000 people in 2009 to 0.87 per 100,000 people in 2018. 8 Potential risk factors for biliary tract tumors include chronic biliary diseases such as primary biliary cholangitis and cholelithiasis; cirrhosis and hepatitis, especially hepatitis B or C; genetic factors like Lynch syndrome and familial adenomatous polyposis may increase the risk of biliary tract tumors in p -Abstract Truncated-
oncology